• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

纳洛酮用于预防阿片类药物所致便秘的研究

[Survey of Prophylactic Administration of Naldemedine for Opioid-induced Constipation].

作者信息

Ozawa Yuki, Haruki Yayoi, Ohata Meiko, Isono Hisayo, Takahashi Minami, Tate Aki, Ukita Seiko, Hayashi Seiichi

机构信息

Department of Phamacy, Kanagawa Prefectural Keiyukai Keiyu Hospital.

Department of Palliative Care Internal Medicine, Kanagawa Prefectural Keiyukai Keiyu Hospital.

出版信息

Yakugaku Zasshi. 2023;143(2):183-189. doi: 10.1248/yakushi.22-00181.

DOI:10.1248/yakushi.22-00181
PMID:36724931
Abstract

Opioid-induced constipation (OIC), an adverse event that occurs due to opioid analgesics, reportedly causes poor quality of life and adherence to opioid analgesics in patients. Therefore, this issue must be addressed appropriately. Naldemedine (NAL), a peripherally-acting μ-opioid receptor antagonist, is currently recommended for treating OIC when other laxatives are ineffective, but there have been no clinical reports of NAL being used prophylactically for OIC. Therefore, we conducted a retrospective survey of hospitalized patients who received NAL as prophylaxis for OIC with strong opioid analgesics to clarify the reality of this situation and to consider points to be taken into account in its clinical implementation. In this study, 61.7% of the subjects had an Eastern Cooperative Oncology Group performance status score of 3 or higher. The rate of addition of new laxatives and increased laxatives during seven days of NAL prophylaxis was 46.8%, and the rate of diarrhea was 6.1%. This study suggests that patients initiated with strong opioid analgesics during hospitalization often presented with poor performance status, and it is important to pay attention to constipation even under NAL prophylaxis. However, the incidence of diarrhea was low, and the safety of NAL prophylaxis was considered to be good.

摘要

阿片类药物引起的便秘(OIC)是一种由阿片类镇痛药导致的不良事件,据报道会导致患者生活质量下降以及对阿片类镇痛药的依从性降低。因此,必须妥善解决这个问题。纳洛酮(NAL)是一种外周作用的μ-阿片受体拮抗剂,目前推荐在其他泻药无效时用于治疗OIC,但尚无关于NAL预防性用于OIC的临床报告。因此,我们对接受NAL作为使用强效阿片类镇痛药时OIC预防措施的住院患者进行了一项回顾性调查,以阐明这种情况的实际情况,并考虑其临床实施中需要考虑的要点。在本研究中,61.7%的受试者东部肿瘤协作组体能状态评分为3分或更高。在NAL预防的七天内添加新泻药和增加泻药的比例为46.8%,腹泻发生率为6.1%。本研究表明,住院期间开始使用强效阿片类镇痛药的患者通常表现为体能状态较差,即使在NAL预防的情况下,关注便秘也很重要。然而,腹泻的发生率较低,NAL预防的安全性被认为良好。

相似文献

1
[Survey of Prophylactic Administration of Naldemedine for Opioid-induced Constipation].纳洛酮用于预防阿片类药物所致便秘的研究
Yakugaku Zasshi. 2023;143(2):183-189. doi: 10.1248/yakushi.22-00181.
2
Pharmacological prevention and treatment of opioid-induced constipation in cancer patients: A systematic review and meta-analysis.癌症患者阿片类药物所致便秘的药理预防与治疗:一项系统评价和荟萃分析
Cancer Treat Rev. 2024 Apr;125:102704. doi: 10.1016/j.ctrv.2024.102704. Epub 2024 Mar 1.
3
Analysis of Predictive Factors for Diarrhea after the Administration of Naldemedine.分析纳洛肽给药后腹泻的预测因素。
Biol Pharm Bull. 2021;44(8):1081-1087. doi: 10.1248/bpb.b21-00209.
4
Efficacy and Safety of Naldemedine Administration for Opioid-Induced Constipation in Cancer Patients with Poor Performance Status.纳地美定用于体能状态较差的癌症患者阿片类药物所致便秘的疗效与安全性
J Palliat Med. 2023 Apr;26(4):548-553. doi: 10.1089/jpm.2022.0495. Epub 2023 Mar 27.
5
A Retrospective Observational Study of Factors Affecting the Efficacy of Concurrent Prescription of Naldemedine for Opioid-Induced Constipation Caused by Oxycodone Tablets.一项回顾性观察研究:影响纳洛酮治疗羟考酮片所致阿片类药物诱导性便秘疗效的因素。
Biol Pharm Bull. 2023;46(12):1826-1831. doi: 10.1248/bpb.b23-00487.
6
Efficacy and Safety of Naldemedine for Opioid-Induced Constipation in Children.纳地美定用于儿童阿片类药物所致便秘的疗效与安全性
J Palliat Med. 2024 Oct;27(10):1354-1358. doi: 10.1089/jpm.2024.0018. Epub 2024 Aug 9.
7
Factors associated with non-response to naldemedine for opioid-induced constipation in cancer patients: A subgroup analysis.与癌症患者中纳洛酮治疗阿片类药物引起的便秘无应答相关的因素:亚组分析。
PLoS One. 2022 Dec 9;17(12):e0278823. doi: 10.1371/journal.pone.0278823. eCollection 2022.
8
A Retrospective Study of the Efficacy and Safety of Naldemedine for Treatment of Opioid-Induced Constipation in Patients with Hepatobiliary Pancreatic Cancer.纳洛酮治疗肝胆胰腺肿瘤患者阿片类药物诱导性便秘的疗效和安全性的回顾性研究。
Medicina (Kaunas). 2023 Mar 2;59(3):492. doi: 10.3390/medicina59030492.
9
Emerging therapies for opioid-induced constipation: what can we expect?阿片类药物引起的便秘的新兴治疗方法:我们能期待什么?
Expert Opin Pharmacother. 2024 Sep;25(13):1729-1738. doi: 10.1080/14656566.2024.2407013. Epub 2024 Sep 23.
10
Prevention and management of diarrhea associated with naldemedine among patients receiving opioids: a retrospective cohort study.接受阿片类药物治疗的患者中与纳地美定相关腹泻的预防和管理:一项回顾性队列研究。
BMC Gastroenterol. 2020 Jan 31;20(1):25. doi: 10.1186/s12876-020-1173-z.